CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 93 enrolled
Drug / intervention
Fluoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00288574
NCT00288574Phase 4Completed
CompareCT.gov

Fluoxetine After Weight Restoration in Anorexia Nervosa

New York State Psychiatric Institute·interventional·Posted Feb 8, 2006·Updated Dec 13, 2017

In Brief

A Phase 4 clinical trial evaluating Fluoxetine and Placebo for Anorexia Nervosa and Eating Disorders. Completed, enrolled 93 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery of people who have been treated for AN.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia Nervosa, Eating Disorders
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 8, 2006
Enrollment StartJan 1, 2000
Primary CompletionMay 1, 2005
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 20.4 years ago

Interventions

Fluoxetinedrug

Placebodrug